<DOC>
	<DOCNO>NCT01327339</DOCNO>
	<brief_summary>post-marketing surveillance monitor safety efficacy ropinirole use treatment RLS</brief_summary>
	<brief_title>REQUIP RLS Post Marketing Surveillance</brief_title>
	<detailed_description>This study post-marketing surveillance monitor safety efficacy ropinirole use treatment RLS ( restless leg syndrome ) identify SAEs , adverse drug reaction , unexpected AEs describe precaution warning identify prognostic factor effect AEs ass effectiveness ropinirole real clinical practice marketing . The subject patient prescribed ropinirole investigator site base prescription information normal clinical practice .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Psychomotor Agitation</mesh_term>
	<mesh_term>Restless Legs Syndrome</mesh_term>
	<mesh_term>Ropinirole</mesh_term>
	<criteria>Subjects diagnose RLS investigator Subjects investigator believe comply requirement protocol To contactable phone To follow administration regimen . A male female age 18 year time first prescription . Subjects experience RLS treatment use ropinirole Considering nature noninterventional PMS study , strict exclusion criterion set . GSK Korea encourage doctor participate study enrol subject prescribed Ropinirole follow locally approve Prescribing Information ( Appendix ) The following criterion check time study entry . Subjects hypersensitivity ropinirole excipients Female period pregnancy lactate</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
</DOC>